Human Organoid Complete Medium
Human Thyroid Cancer Organoid Complete Medium
Catalog Number: GBCM0038
Click to request a quote.
Contact our team for a special quote, free sample request, Protocols, COA, SDS, or other technical consultation. Our specialists are ready to help you find the right solution for your research.
Product Specifications
| Product Name | Human Thyroid Cancer Organoid Complete Medium |
|---|---|
| Size | 100mL |
| Quality Control Standards | pH: 7.2~7.4Endotoxin content: <10 EU/mLBiosafety: Negative for bacteria, fungi, and mycoplasma detectionPerformance test: Passed organoid culture test |
| Storage Condition | Store at -20℃,valid for 6 months.Store at 2-8℃valid for 2 weeks.Once thawed, use immediately. Do not refreeze. Can be aliquoted and stored according to your needs. |
| Precautions | Upon receipt, store immediately in a -20°C freezer, or aliquot and store in a 2-8°C refrigerator.When unpacking, check for any leakage or damage.Use aseptic techniques during product handling to avoid contamination. |
Product Description
Cell Source and Tissue Characteristics:
Human thyroid cancer organoids are derived from tumor tissue surgically removed from patients with papillary thyroid cancer (PTC), follicular cancer (FTC), undifferentiated cancer (ATC/anaplastic cancer) or medullary cancer (MTC).Thyroid cancer is the most common endocrine malignancy, accounting for more than 80% of all thyroid cancer.Common driver mutations of PTC include BRAF V600E (40-60%), RAS mutations, and RET/PTC rearrangements.TP53 and PTEN mutations are common in ATC.Thyroid cancer organoids retain tumor mutation profiles and histological characteristics, and can be used for radioactive iodine refractory screening, targeted drug testing, and personalized treatment.
Human thyroid cancer organoids are derived from tumor tissue surgically removed from patients with papillary thyroid cancer (PTC), follicular cancer (FTC), undifferentiated cancer (ATC/anaplastic cancer) or medullary cancer (MTC).Thyroid cancer is the most common endocrine malignancy, accounting for more than 80% of all thyroid cancer.Common driver mutations of PTC include BRAF V600E (40-60%), RAS mutations, and RET/PTC rearrangements.TP53 and PTEN mutations are common in ATC.Thyroid cancer organoids retain tumor mutation profiles and histological characteristics, and can be used for radioactive iodine refractory screening, targeted drug testing, and personalized treatment.
Human Thyroid Cancer Organoid Complete Medium is a high-performance complete medium specifically designed for Human Thyroid Cancer Organoid culture. This advanced formulation employs optimized nutrient composition and growth factor cocktails to precisely mimic the in vivo tissue microenvironment, supporting long-term establishment, expansion, and maintenance of organoids from primary tissue samples.
Human Thyroid Cancer Organoid Complete Medium is suitable for multiple applications including precision medicine research, high-throughput drug screening, toxicity testing, developmental biology studies, and organoid biobanking. The product undergoes rigorous quality control including sterility testing, endotoxin detection, functional validation using established organoid lines, and batch-to-batch consistency checks.
Human Thyroid Cancer Organoid Complete Medium is suitable for multiple applications including precision medicine research, high-throughput drug screening, toxicity testing, developmental biology studies, and organoid biobanking. The product undergoes rigorous quality control including sterility testing, endotoxin detection, functional validation using established organoid lines, and batch-to-batch consistency checks.
Notes
- For research use only. Not for diagnostic or therapeutic procedures.
- All products undergo rigorous quality testing including sterility and performance validation.
- Contact our support team for protocol optimization and troubleshooting assistance.
- More validation data are prepared for uploading.